Rtz DL, Yen Revollo J, Paul J, He Y, et al. Cumulative genetic possibility predicts platinum/taxane-induced neurotoxicity. Clin Cancer Res. 2013;19:57696. four. Yap TA, Carden CP, Kaye SB. Further than chemotherapy: focused therapies in ovarian most cancers. Nat Rev Cancer. 2009;nine:1671. 5. Wu R, Hu TC, Rehemtulla A, Fearon ER, Cho KR. Preclinical testing of PI3K/ AKT/mTOR signaling inhibitors in the mouse model of ovarian endometrioid adenocarcinoma. Clin Most cancers Res. 2011;17:73592. 6. Mabuchi S, Kuroda H, Takahashi R, Sasano T. The PI3K/AKT/mTOR pathway being a therapeutic concentrate on in ovarian cancer. Gynecol Oncol. 2015;137(one):173. 7. Lau MT, So WK, Leung Personal computer. Fibroblast advancement variable 2 induces E-cadherin down-regulation through PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer cells. PLoS A single. 2013;eight:e59083. eight. Yang YI, Ahn JH, Lee KT, Shih Ie M, Choi JH. RSF1 can be a positive regulator of NFkappaB-induced gene expression needed for ovarian cancer chemoresistance. Cancer Res. 2014;74:22589. nine. Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, et al. Section II trial with the mTOR inhibitor, temsirolimus and analysis ofLiu et al. Journal of Ovarian Investigate (2015) 8:Web page 9 of10.11.twelve.thirteen. fourteen. fifteen. 16.17. eighteen. 19.20.21.22.23. 24. 25.26. 27. 28.circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and first peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;123:196. Turner JG, Dawson J, Cubitt CL, Baz R, Sullivan DM. Inhibition of CRM1dependent 136817-59-9 custom synthesis nuclear export sensitizes malignant cells to cytotoxic and focused brokers. Semin Most cancers Biol. 2014;27:623. Noske A, Weichert W, Niesporek S, Roske A, Buckendahl AC, Koch I, et al. Expression in the nuclear export 832115-62-5 supplier protein chromosomal area maintenance/ exportin 1/Xpo1 is often a prognostic element in human ovarian most cancers. Cancer. 2008;112:17333. Wang Y, Xiang J, Ji F, Deng Y, Tang C, Yang S, et al. Knockdown of CRM1 inhibits the nuclear export of p27(Kip1) phosphorylated at serine ten and plays a task in the pathogenesis of epithelial ovarian cancer. Cancer Lett. 2014;343:sixty three. Mor A, White MA, Fontoura BM. Nuclear trafficking in well being and disorder. Curr Opin Cell Biol. 2014;28:285. Fung HY, Chook YM. Atomic foundation of CRM1-cargo recognition, launch and inhibition. Semin Most cancers Biol. 2014;27:521. Parikh K, Cang S, Sekhri A, Liu D. Selective inhibitors of nuclear export (SINE) novel course of anti-cancer 30516-87-1 Autophagy agents. J Hematol Oncol. 2014;7:seventy eight. Liu X, Niu M, Xu X, Cai W, Zeng L, Zhou X, et al. CRM1 can be a immediate cellular target with the pure anti-cancer agent plumbagin. J Pharmacol Sci. 2014;124:4863. Newlands ES, Rustin GJ, Brampton MH. Stage I demo of elactocin. Br J Most cancers. 1996;74:648. Gerecitano J. SINE (selective inhibitor of nuclear export) ranslational science inside of a new class of anti-cancer agents. J Hematol Oncol. 2014;7:67. Liu X, Cai W, Niu M, Chong Y, Liu H, Hu W, et al. Plumbagin induces progress inhibition of human glioma cells by downregulating the expression and activity of FOXM1. J Neurooncol. 2015;121:4697. Niu M, Sunlight Y, Liu X, Tang L, Qiu R. Tautomycetin induces apoptosis by inactivating Akt by way of a PP1-independent signaling pathway in human breast most cancers cells. J Pharmacol Sci. 2013;121:174. Sunlight Q, Carrasco YP, Hu Y, Guo X, Mirzaei H, Macmillan J, et al. Nuclear export inhibition via covalent conjugation and hydrolysis of Leptomycin B by CRM1. Proc Natl Acad Sci U S A. 2013;one hundred ten:1303. Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM, Matzuk MM.
